

MOROCCO

Number of new cases

63 609

Number of deaths

36 947

Number of prevalent cases (5-year)

154 884


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	18 762 419	19 010 338	37 772 757
Incidence*			
Number of new cancer cases	30 737	32 872	63 609
Age-standardized incidence rate	150.8	150.3	149.8
Risk of developing cancer before the age of 75 years (cum. risk %)	15.9	15.1	15.5
Top 3 leading cancers (ranked by cases)**	Lung Prostate Colorectum	Breast Cervix uteri Colorectum	Breast Lung Colorectum
Mortality*			
Number of cancer deaths	21 155	15 792	36 947
Age-standardized mortality rate	105.0	70.5	85.9
Risk of dying from cancer before the age of 75 years (cum. risk %)	10.5	7.6	9.1
Top 3 leading cancers (ranked by deaths)**	Lung Prostate Colorectum	Breast Cervix uteri Colorectum	Lung Breast Colorectum
Prevalence*			
5-year prevalent cases	65 211	89 673	154 884



Top 5 most frequent cancers**

Males




Total: 30 737

Rank	Cancer site	Number of cases	Percent
1st	Lung	7 884	25.6%
2nd	Prostate	4 935	16.1%
3rd	Colorectum	2 752	9.0%
4th	Bladder	1 911	6.2%
5th	Stomach	1 402	4.6%
-	Others	11 853	38.6%

Number of new cases in 2022, males, all ages

Females




Total: 32 872

Rank	Cancer site	Number of cases	Percent
1st	Breast	12 756	38.8%
2nd	Cervix uteri	2 644	8.0%
3rd	Colorectum	2 554	7.8%
4th	Thyroid	2 458	7.5%
5th	Ovary	1 367	4.2%
-	Others	11 093	33.7%

Number of new cases in 2022, females, all ages

Both sexes



Total: 63 609

Rank	Cancer site	Number of cases	Percent
1st	Breast	12 756	20.1%
2nd	Lung	8 825	13.9%
3rd	Colorectum	5 306	8.3%
4th	Prostate	4 935	7.8%
5th	Thyroid	2 861	4.5%
-	Others	28 926	45.5%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	12 756	1	20.1	6.1	4 044	2	10.9	2.0	37 605	197.8
Lung	8 825	2	13.9	2.5	7 970	1	21.6	2.2	11 764	31.1
Colorectum	5 306	3	8.3	1.4	2 892	3	7.8	0.73	14 157	37.5
Prostate	4 935	4	7.8	2.9	2 030	5	5.5	0.59	10 852	57.8
Thyroid	2 861	5	4.5	0.70	356	21	0.96	0.08	8 975	23.8
Cervix uteri	2 644	6	4.2	1.4	1 468	6	4.0	0.81	7 383	38.8
NHL	2 381	7	3.7	0.61	1 323	7	3.6	0.33	6 896	18.3
Stomach	2 355	8	3.7	0.61	2 075	4	5.6	0.54	3 641	9.6
Bladder	2 207	9	3.5	0.62	1 222	8	3.3	0.30	6 225	16.5
Leukaemia	1 502	10	2.4	0.34	1 078	11	2.9	0.25	4 274	11.3
Brain CNS	1 389	11	2.2	0.34	1 119	10	3.0	0.28	4 738	12.5
Ovary	1 367	12	2.1	0.71	919	13	2.5	0.51	3 687	19.4
Pancreas	1 229	13	1.9	0.36	1 181	9	3.2	0.34	1 349	3.6
Larynx	1 195	14	1.9	0.35	793	14	2.1	0.23	3 390	9.0
Liver	1 112	15	1.7	0.30	1 047	12	2.8	0.28	1 469	3.9
Nasopharynx	987	16	1.6	0.25	580	15	1.6	0.16	2 926	7.8
Corpus uteri	918	17	1.4	0.55	211	23	0.57	0.13	2 976	15.7
Hodgkin lymphoma	799	18	1.3	0.17	253	22	0.69	0.06	2 624	7.0
Kidney	752	19	1.2	0.19	412	18	1.1	0.10	2 117	5.6
Lip, oral cavity	705	20	1.1	0.18	386	19	1.0	0.09	1 847	4.9
Multiple myeloma	549	21	0.86	0.15	482	16	1.3	0.12	1 403	3.7
Gallbladder	530	22	0.83	0.15	373	20	1.0	0.10	791	2.1
Oesophagus	433	23	0.68	0.12	415	17	1.1	0.11	641	1.7
Melanoma	236	24	0.37	0.06	118	24	0.32	0.03	718	1.9
Vulva	206	25	0.32	0.10	89	26	0.24	0.03	543	2.9
Salivary glands	167	26	0.26	0.04	97	25	0.26	0.02	469	1.2
Testis	156	27	0.25	0.06	31	31	0.08	0.01	544	2.9
Hypopharynx	129	28	0.20	0.03	72	27	0.20	0.02	217	0.57
Oropharynx	110	29	0.17	0.03	61	30	0.17	0.02	264	0.70
Kaposi sarcoma	107	30	0.17	0.02	64	29	0.17	0.01	233	0.62
Mesothelioma	69	31	0.11	0.02	67	28	0.18	0.02	100	0.26
Vagina	66	32	0.10	0.04	29	32	0.08	0.02	169	0.89
All cancers	63 609	-	-	15.5	36 947	-	-	9.1	154 884	-
All cancers excl. NMSC	63 110	-	-	15.4	36 754	-	-	9.0	153 388	-

Data source and methods

Incidence



Country-specific data source: Casablanca cancer registry, Rabat cancer registry
 Method: Weighted/simple average of the most recent sub-national rates applied to 2022 population

Mortality

Country-specific data source: No data
 Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-; site- and age-specific incidence to 1-;3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

